| scholarly article | Q13442814 |
| P50 | author | Julio A Ramirez | Q59558816 |
| P2093 | author name string | Paula Peyrani | |
| Daniel H Kett | |||
| Kimbal D Ford | |||
| Marcus J Zervos | |||
| Cynthia M Cely | |||
| Ernesto G Scerpella | |||
| Verna L Welch | |||
| Nadia Z Haque | |||
| Ennie L Cano | |||
| Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Study Group | |||
| P433 | issue | 1 | |
| P921 | main subject | patient | Q181600 |
| vancomycin | Q424027 | ||
| pneumonia | Q12192 | ||
| database | Q8513 | ||
| intensive care unit | Q5094647 | ||
| P304 | page(s) | 149-157 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | Clinical Therapeutics | Q15716601 |
| P1476 | title | Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database. | |
| P478 | volume | 34 |
| Q92947418 | A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections |
| Q44403470 | A randomized trial of loading vancomycin in the emergency department |
| Q38261172 | Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much". |
| Q40254585 | Are Elevated Vancomycin Serum Trough Concentrations Achieved Within the First 7 Days of Therapy Associated With Acute Kidney Injury in Children? |
| Q37544400 | Are vancomycin trough concentrations adequate for optimal dosing? |
| Q41255520 | Assessment of initial serum vancomycin trough concentrations and their association with initial empirical weight-based vancomycin dosing and development of nephrotoxicity in children: a multicenter retrospective study |
| Q39044128 | Balancing vancomycin efficacy and nephrotoxicity: should we be aiming for trough or AUC/MIC? |
| Q36216479 | Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? |
| Q38409273 | Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study. |
| Q33939091 | Comparative Incidence of Nephrotoxicity by Age Group among Adult Patients Receiving Vancomycin |
| Q93110539 | Comparative Performance of Urinary Biomarkers for Vancomycin-Induced Kidney Injury According to Timeline of Injury |
| Q35780121 | Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia |
| Q28071882 | Current and Future Considerations for the Treatment of Hospital-Acquired Pneumonia |
| Q44770615 | Development of acute kidney injury during continuous infusion of vancomycin in septic patients. |
| Q40363114 | Eight unexpected cases of vancomycin associated acute kidney injury with contemporary dosing. |
| Q34396004 | Empiric weight-based vancomycin in intensive care unit patients with methicillin-resistant Staphylococcus aureus bacteremia. |
| Q89743203 | Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia |
| Q26823518 | European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid |
| Q57216392 | Evaluation of risk factors for vancomycin-induced nephrotoxicity |
| Q54995486 | Evaluation of the Risk for Acute Kidney Injury in Adult Cystic Fibrosis Patients Receiving Concomitant Vancomycin and Tobramycin. |
| Q35123536 | High versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis |
| Q90150691 | How Much Vancomycin Dose Is Enough For The MRSA Infection in Pediatric Patients With Various Degrees of Renal Function? |
| Q94063596 | Incidence and Risk Factors for Vancomycin Nephrotoxicity in Acutely Ill Pediatric Patients |
| Q40330013 | Incidence and risk factors of acute kidney injury associated with continuous intravenous high-dose vancomycin in critically ill patients: A retrospective cohort study |
| Q41393065 | Is procalcitonin-guided antimicrobial use cost-effective in adult patients with suspected bacterial infection and sepsis? |
| Q41115090 | Late-Occurring Vancomycin-Associated Acute Kidney Injury in Children Receiving Prolonged Therapy |
| Q35960929 | Nephrotoxicity comparison of two commercially available generic vancomycin products. |
| Q37612957 | Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime |
| Q40964689 | Pharmacokinetic Characteristics and Clinical Outcomes of Vancomycin in Young Children With Various Degrees of Renal Function |
| Q26746932 | Review of vancomycin-induced renal toxicity: an update |
| Q53698257 | Risk of acute kidney injury in critically ill surgical patients with presumed pneumonia is not impacted by choice of methicillin-resistant staphylococcus aureus therapy. |
| Q33887897 | Risk of surgical site infection, acute kidney injury, and Clostridium difficile infection following antibiotic prophylaxis with vancomycin plus a beta-lactam versus either drug alone: A national propensity-score-adjusted retrospective cohort study. |
| Q33892706 | Standard operating procedures for antibiotic therapy and the occurrence of acute kidney injury: a prospective, clinical, non-interventional, observational study |
| Q38061039 | Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter |
| Q41729033 | The 2016 Guidelines for Hospital-acquired and Ventilator-associated Pneumonia. A Selection Correction? |
| Q38687487 | The Nephrotoxicity of Vancomycin |
| Q33885191 | The Whole Price of Vancomycin: Toxicities, Troughs, and Time |
| Q100559010 | The comparative risk of acute kidney injury of vancomycin relative to other common antibiotics |
| Q30278491 | Top Guns: The "Maverick" and "Goose" of Empiric Therapy |
| Q91838866 | Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model |
| Q38139926 | Using quality improvement principles to improve the care of patients with severe sepsis and septic shock |
| Q98161958 | Validation of the usefulness of artificial neural networks for risk prediction of adverse drug reactions used for individual patients in clinical practice |
| Q48089081 | Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice |
| Q30409849 | Vancomycin and nephrotoxicity: just another myth? |
| Q30278775 | Vancomycin-Associated Nephrotoxicity: The Obesity Factor |
| Q42220619 | Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors. |
| Q38249103 | Vancomycin-associated renal dysfunction: where are we now? |
| Q37992997 | Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review |
| Q38542797 | Vancomycin: the tale of the vanquisher and the pyrrhic victory. |
Search more.